<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185744</url>
  </required_header>
  <id_info>
    <org_study_id>BRSNSTU0003</org_study_id>
    <secondary_id>78466</secondary_id>
    <secondary_id>BRSNSTU0003</secondary_id>
    <secondary_id>IRB-13807</secondary_id>
    <nct_id>NCT00185744</nct_id>
  </id_info>
  <brief_title>Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer</brief_title>
  <official_title>Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether an accelerated course of radiotherapy delivered to the lumpectomy cavity
      plus margin using IORT as a single dose, intracavitary brachytherapy with the MammoSite
      device over 5 days, partial breast 3-D CRT in 5 days, or stereotactic APBI over 4 days is a
      feasible and safe alternative to a six and a half week course of whole breast radiotherapy.
      The study will measure both short and long-term complications of radiation treatment, short
      and long-term breast cosmesis, local rates of in-breast cancer recurrence, regional
      recurrences, distant metastases, and overall survival.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">March 2029</completion_date>
  <primary_completion_date type="Anticipated">March 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-breast tumor recurrence (IBTR)</measure>
    <time_frame>20 years</time_frame>
    <description>Proportion of subjects that experience in-breast tumor recurrence (IBTR), to be assessed through or by March 2029</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Carcinoma, Ductal</condition>
  <arm_group>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lumpectomy with accelerated partial breast irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lumpectomy and whole breast irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intra-Operative Radiotherapy (IORT)</intervention_name>
    <description>single dose in the operating room after lumpectomy</description>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumpectomy</intervention_name>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole Breast Radiotherapy</intervention_name>
    <description>six and a half week treatment</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intracavitary Brachytherapy</intervention_name>
    <description>5 day treatment</description>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
    <other_name>MammoSite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated External Beam 3-D Conformal Radiotherapy</intervention_name>
    <description>5 day treatment</description>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic APBI</intervention_name>
    <description>4 day treatment</description>
    <arm_group_label>Accelerated Partial Breast Irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women &gt;= 40 with invasive ductal carcinoma or ductal carcinoma in situ

          2. Patient chooses lumpectomy rather than mastectomy as treatment for breast cancer

          3. Tumor &lt; 2.5 cm in size, 2 mm margin of normal breast tissue between cancer and edge of
             specimen.

        Exclusion Criteria:

          1. Men

          2. Prior malignancy, breast or other if metastatic or with anticipated survival of &lt; 5
             years

          3. Pregnant women

          4. Immunocompromised

          5. Poorly controlled insulin dependent diabetes

          6. Contraindication to radiotherapy, e.g. connective tissue disorder such as scleroderma

          7. Breast cancer that involves skin or chest wall

          8. Multifocal or Multicentric breast cancer

          9. Invasive lobular carcinoma

         10. Diffuse microcalcifications on mammography

         11. Invasive carcinoma with extensive intraductal component (EIC)

         12. Greater than 12 weeks since definitive surgical excision or completion of chemotherapy

         13. Involved lymph nodes detected by frozen section or touch preparation at time of
             lumpectomy

         14. Patients with 1 to 3 positive lymph nodes determined postoperatively (does not include
             patients with micro-metastases)

         15. Subglandular or submuscular breast implants (does not include patients having implants
             placed AFTER intra-operative radiotherapy)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick M. Dirbas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

